Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients

Figure 1 Podoplanin expression and prognosis of squamous cell carcinoma of the esophagus patients. Podoplanin expression in resected specimen of non-pretreated squamous cell carcinoma of the esophagus patients.

Figure 2 Podoplanin expression pre- and post-neoadjuvant treatment. A and D: Pre-treatment biopsies of two patients with podoplanin expression of scores: 3 (A) and 2 (D); B and E: Matching resection specimen of the same squamous cell carcinoma of the esophagus (ESCC) patients after chemoradiation, Scores: 1 (B), 2 (E); C and F: Resection specimen of two ESCC patients without neoadjuvant treatment, scores: 2 (C), 3 (F), at T-category 3; 40 ×. Score 1: 0-5% tumor cells stained by D2-40 mab, score 2: 6%-35%, score 3: 36%-65%. ESCC: Squamous cell carcinoma of the esophagus.

Figure 3 miR-363 and podoplanin expression for 29 non-pretreated squamous cell carcinoma of the esophagus patients. Relative miR-363 expression compared to immunohistochemically stained podoplanin protein expression in resected tissue specimen.

Figure 4 miR-363 expression and prognosis of 26 squamous cell carcinoma of the esophagus patients. Subgrouping by relative miR-363 expression < 7 and ≥ 7.